. 2019 Jul 15;8(8):1159–1167. doi: 10.1530/EC-19-0243
This work is licensed under a Table 1.
Clinical and biochemical characteristics of the studied groups.
| Control group (n = 51) | PCOS (n = 57) | P value | |
|---|---|---|---|
| Age (years) | 26.3 ± 4.3 | 25.6 ± 4.7 | 0.40 |
| BMI (kg/m2) | 22.8 ± 3.1 | 23.9 ± 3.7 | 0.07 |
| Waist circumference (cm) | 79.5 ± 8.3 | 82.2 ± 10.0 | 0.13 |
| Hip circumference (cm) | 98.7 ± 7.1 | 99.4 ± 8.1 | 0.60 |
| Fat free mass (kg) | 44.8 ± 3.7 | 44.8 ± 5.0 | 0.78 |
| Fat mass (%) | 28.9 ± 6.3 | 31.7 ± 8.6 | 0.06 |
| Follicle-stimulating hormone (IU/L) | 5.4 ± 1.7 | 5.4 ± 1.4 | 0.90 |
| Luteinizing hormone (IU/L) | 4.1 ± 1.2 | 5.1 ± 2.3a | 0.01 |
| Total testosterone (ng/mL) | 0.56 ± 0.1 | 0.75 ± 0.4a | 0.01 |
| SHBG (nmol/L) | 66.0 ± 30.2 | 56.5 ± 46.1 | 0.21 |
| FAI | 3.4 ± 2.5 | 6.8 ± 6.2a | <0.01 |
| Prolactin (ng/mL) | 15.5 ± 14.0 | 16.2 ± 13.4 | 0.79 |
| Glucose 0′ OGTT (mg/dL) | 94.1 ± 9.5 | 92.0 ± 7.1 | 0.18 |
| Glucose 60′ OGTT (mg/dL) | 97.7 ± 20.5 | 115 ± 36.5a | 0.003 |
| Glucose 120′ OGTT (mg/dL) | 88.8 ± 16.6 | 95.8 ± 22.2 | 0.06 |
| Insulin 0′ OGTT (µIU/mL) | 10.0 ± 4.8 | 9.7 ± 4.0 | 0.72 |
| Insulin 60′ OGTT (µIU/mL) | 55.9 ± 45.8 | 71.0 ± 50.5 | 0.10 |
| Insulin 120′ OGTT (µIU/mL) | 30. ± 18.3 | 46.9 ± 53.2a | 0.03 |
| HOMA-IR | 2.2 ± 1.1 | 2.3 ± 1.0 | 0.65 |
| HOMA-B | 125 ± 70 | 125 ± 56 | 0.11 |
| Total cholesterol (mg/dL) | 175 ± 28.1 | 169 ± 25 | 0.23 |
| HDL-cholesterol (mg/dL) | 65.7 ± 20.7 | 71.4 ± 16.4 | 0.11 |
| LDL-cholesterol (mg/dL) | 91.5 ± 24.3 | 89.6 ± 21.6 | 0.67 |
| TG (mg/dL) | 62.0 ± 28.0 | 69.3 ± 39.6 | 0.27 |
| Fetuin-B (µg/mL) | 79.2 ± 16.7 | 88.1 ± 26.7a | 0.04 |
| VAI | 0.78 ± 0.48 | 1.01 ± 1.04 | 0.15 |
| LAP | 15.7 ± 10.7 | 21.0 ± 22.7 | 0.13 |
| FLI | 8.0 ± 10.2 | 14.4 ± 19.6a | 0.02 |
| GGT | 9.4 ± 2.7 | 13.1 ± 8.2a | 0.02 |
Data are presented as mean ± s.d. The level of significance was accepted at aP < 0.05.
BMI, body mass index; FAI, free androgen index; FLI, fatty liver index; GGT, gamma-glutamyl transferase; HOMA-B, homeostatic model assessment β cell function; HOMA-IR, homeostasis model assessment of insulin resistance; LAP, lipid accumulation product; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; SHBG, serum sex hormone–binding globulin; TG, triglycerides; VAI, visceral adiposity index.